merck & co. inc. - MRK

MRK

Close Chg Chg %
77.82 -0.22 -0.28%

Closed Market

77.60

-0.22 (0.28%)

Volume: 10.90M

Last Updated:

May 23, 2025, 3:59 PM EDT

Company Overview: merck & co. inc. - MRK

MRK Key Data

Open

$77.55

Day Range

77.08 - 77.90

52 Week Range

73.31 - 134.63

Market Cap

$195.46B

Shares Outstanding

2.51B

Public Float

2.51B

Beta

0.45

Rev. Per Employee

N/A

P/E Ratio

11.33

EPS

$6.89

Yield

405.96%

Dividend

$0.81

EX-DIVIDEND DATE

Mar 17, 2025

SHORT INTEREST

N/A

AVERAGE VOLUME

15.58M

 

MRK Performance

1 Week
 
2.34%
 
1 Month
 
-5.92%
 
3 Months
 
-13.03%
 
1 Year
 
-39.89%
 
5 Years
 
1.92%
 

MRK Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 26
Full Ratings ➔

About merck & co. inc. - MRK

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

MRK At a Glance

Merck & Co., Inc.
126 East Lincoln Avenue
Rahway, New Jersey 07065
Phone 1-908-740-4000 Revenue 63.97B
Industry Pharmaceuticals: Major Net Income 17.12B
Sector Health Technology 2024 Sales Growth 6.851%
Fiscal Year-end 12 / 2025 Employees 75,000
View SEC Filings

MRK Valuation

P/E Current 11.332
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 14.768
Price to Sales Ratio 3.951
Price to Book Ratio 5.429
Price to Cash Flow Ratio 11.775
Enterprise Value to EBITDA 11.048
Enterprise Value to Sales 4.335
Total Debt to Enterprise Value 0.138

MRK Efficiency

Revenue/Employee 852,973.333
Income Per Employee 228,226.667
Receivables Turnover 5.749
Total Asset Turnover 0.572

MRK Liquidity

Current Ratio 1.365
Quick Ratio 1.15
Cash Ratio 0.484

MRK Profitability

Gross Margin 73.736
Operating Margin 32.209
Pretax Margin 31.163
Net Margin 26.757
Return on Assets 15.298
Return on Equity 40.806
Return on Total Capital 20.237
Return on Invested Capital 22.252

MRK Capital Structure

Total Debt to Total Equity 82.633
Total Debt to Total Capital 45.245
Total Debt to Total Assets 32.68
Long-Term Debt to Equity 76.305
Long-Term Debt to Total Capital 41.78
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Merck & Co. Inc. - MRK

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
48.91B 58.47B 59.87B 63.97B
Sales Growth
+1.86% +19.56% +2.39% +6.85%
Cost of Goods Sold (COGS) incl D&A
13.47B 17.21B 15.98B 16.80B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
3.21B 3.91B 3.87B 4.50B
Depreciation
1.58B 1.82B 1.83B 2.10B
Amortization of Intangibles
1.64B 2.08B 2.04B 2.40B
COGS Growth
+6.94% +27.77% -7.14% +5.16%
Gross Income
35.44B 41.27B 43.89B 47.17B
Gross Income Growth
+0.06% +16.44% +6.37% +7.47%
Gross Profit Margin
+72.47% +70.57% +73.31% +73.74%
2021 2022 2023 2024 5-year trend
SG&A Expense
19.82B 21.77B 40.91B 26.57B
Research & Development
10.21B 11.82B 30.53B 15.83B
Other SG&A
9.62B 9.95B 10.38B 10.73B
SGA Growth
-13.27% +9.81% +87.96% -35.07%
Other Operating Expense
- - - -
-
Unusual Expense
3.16B 2.27B 1.03B 1.14B
EBIT after Unusual Expense
12.46B 17.23B 1.95B 19.46B
Non Operating Income/Expense
2.23B 174.00M 1.08B 1.74B
Non-Operating Interest Income
36.00M 157.00M 365.00M 415.00M
Equity in Earnings of Affiliates
1.94B (1.42B) (106.00M) (29.00M)
Interest Expense
806.00M 962.00M 1.15B 1.27B
Interest Expense Growth
-3.01% +19.35% +19.13% +10.91%
Gross Interest Expense
806.00M 962.00M 1.15B 1.27B
Interest Capitalized
- - - -
-
Pretax Income
13.88B 16.44B 1.89B 19.94B
Pretax Income Growth
+57.88% +18.48% -88.51% +955.37%
Pretax Margin
+28.38% +28.12% +3.16% +31.16%
Income Tax
1.52B 1.92B 1.51B 2.80B
Income Tax - Current - Domestic
61.00M 2.32B 976.00M 929.00M
Income Tax - Current - Foreign
1.27B 1.16B 2.44B 3.12B
Income Tax - Deferred - Domestic
264.00M (1.64B) (1.67B) (1.46B)
Income Tax - Deferred - Foreign
(77.00M) 71.00M (233.00M) 212.00M
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
1.94B (1.42B) (106.00M) (29.00M)
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
12.36B 14.53B 377.00M 17.13B
Minority Interest Expense
13.00M 7.00M 12.00M 16.00M
Net Income
12.35B 14.52B 365.00M 17.12B
Net Income Growth
+74.69% +17.61% -97.49% +4,589.59%
Net Margin Growth
+25.24% +24.83% +0.61% +26.76%
Extraordinaries & Discontinued Operations
- - - 704.00M
-
Discontinued Operations
- - - 704.00M
-
Net Income After Extraordinaries
13.05B 14.52B 365.00M 17.12B
Preferred Dividends
- - - -
-
Net Income Available to Common
13.05B 14.52B 365.00M 17.12B
EPS (Basic)
5.1577 5.7342 0.1439 6.7603
EPS (Basic) Growth
+84.65% +11.18% -97.49% +4,597.92%
Basic Shares Outstanding
2.53B 2.53B 2.54B 2.53B
EPS (Diluted)
5.1414 5.7116 0.1433 6.7363
EPS (Diluted) Growth
+84.86% +11.09% -97.49% +4,600.84%
Diluted Shares Outstanding
2.54B 2.54B 2.55B 2.54B
EBITDA
18.83B 23.41B 6.85B 25.10B
EBITDA Growth
+16.31% +24.30% -70.72% +266.27%
EBITDA Margin
+38.51% +40.04% +11.45% +39.24%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 103.474
Number of Ratings 26 Current Quarters Estimate 2.061
FY Report Date 06 / 2025 Current Year's Estimate 8.904
Last Quarter’s Earnings 2.22 Median PE on CY Estimate N/A
Year Ago Earnings 7.65 Next Fiscal Year Estimate 9.72
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 14 14 21 21
Mean Estimate 2.06 2.46 8.90 9.72
High Estimates 2.30 2.53 9.05 10.33
Low Estimate 1.89 2.33 8.78 8.48
Coefficient of Variance 5.59 2.49 0.73 4.86

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 13 15 13
OVERWEIGHT 3 3 2
HOLD 10 10 10
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Overweight Overweight Overweight

Insider Actions for Merck & Co. Inc. - MRK

Date Name Shares Transaction Value
Apr 2, 2025 Thomas Henry Glocer Director 99,579 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Apr 2, 2025 Christine E. Seidman Director 15,378 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Apr 2, 2025 Mary Ellen Coe Director 24,568 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 21, 2025 Johannes Jacobus Oosthuizen President, U.S. Market 30,705 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $84.09 per share 2,581,983.45
Jun 5, 2024 Pamela J. Craig Director 28,234 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jun 5, 2024 Inge G. Thulin Director 21,229 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jun 5, 2024 Patricia Fiorello Russo Director 53,952 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jun 5, 2024 Risa J. Lavizzo-Mourey Director 12,120 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jun 5, 2024 Douglas M. Baker Director 6,282 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jun 5, 2024 Paul B. Rothman Director 28,234 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jun 5, 2024 Stephen L. Mayo Director 9,380 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jun 5, 2024 Kathy J. Warden Director 12,252 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00

Merck & Co. Inc. in the News